To **Date:** 29/08/2026
The Manager
Corporate Relationship Department,
BSE Limited,
Phiroze Jeejeebhoy Towers, Dalal Street, Fort,
Mumbai - 400001.

Scrip Code: 544759, Scrip ID: GLPL,

Sub: Proceedings of the 22nd Annual General Meeting (AGM) of the Company pertaining to Financial Year 2025-26.

Dear Sir / Ma'am,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with the item 13 of Part –A, Schedule III of the Listing Regulations, we have attached herewith the proceedings of 22nd Annual General Meeting (AGM) of the Company pertaining to Financial Year 2025-26 held on Saturday, August 29, 2026 at 04:00 P.M. and concluded at 05:05 P.M.

For your information and record.

Kindly acknowledge and oblige.

Thanking you,

Yours faithfully,

For Goldline Pharmaceutical Limited

Ruchi Sanket Modi
Digitally signed by Ruchi Sanket Modi
Date: 2026.08.29 20:19:24 +05'30'

Ruchi Sanket Modi
Company Secretary cum Compliance Officer

PROCEEDINGS OF THE 22ND ANNUAL GENERAL MEETING OF THE MEMBERS OF GOLDLINE PHARMACEUTICAL LIMITED HELD ON SATURDAY, 29TH AUGUST, 2026 AT 04:00 P.M. AT HOTEL AIRPORT CENTRE POINT, 131/1, ADJACENT TO AIRPORT, WARDHA ROAD, SOMALWADA, NAGPUR, MAHARASHTRA 440025

The 22nd Annual General Meeting ("AGM") of the Goldline Pharmaceutical Limited ("the Company") was held on Saturday, 29th August 2026 at 04:00 P.M. at Hotel Airport Centre Point, 131/1, Adjacent to Airport, Wardha Road, Somalwada, Nagpur, Maharashtra 440025.

Time of Commencement: 04:00 P.M Time of Conclusion: 05:05 P.M.

1. MEMBERS OF THE BOARD AND KEY MANAGERIAL PERSONNEL PRESENT:

The following Directors and Key Managerial Personnel were present at the Meeting:

1. **Mr. Amol Laxmikant Mujumdar** – Chairman & Managing Director
2. **Mr. Swapan Khandelwal** – Whole-Time Director
3. **Dr. Prashant Rahate** – Non-Executive Director
4. **Mr**. **Prashant Shrikrishna Karkare** – Executive Director
5. **Mr**. **Avinash Pandurang Ambulkar** – Executive Director
6. **Mrs**. **Dipti Sharad Bhusari** – Chief Financial Officer
7. **Mr**. **Mehul Hari Ranade** – Independent Director
8. **Mrs**. **Renuka Saurabh Borole** – Independent Director
9. **Ms**. **Shraddha Kiran Kulkarni** – Independent Director
10. **Ms. Ruchi Modi** – Company Secretary & Compliance Officer

2. INVITEES

The following invitees were present at the Meeting:

1. **CA Nilesh Tiwari** – Statutory Auditor

   (On Behalf of M/s. B Shroff & Co, Chartered Accountants)

2. **CS Avinash Gandhewar** – Secretarial Auditor & Scrutinizer

   (On Behalf of M/s. Avinash Gandhewar & Associates, Practicing Company Secretaries)

3. **CS Kunal Dutt** – Internal Auditor

   (On Behalf of M/s. Kunal Dutt & Associates, Practicing Company Secretaries)

3. MEMBERS

Total 15 Members, including authorised representatives, attended the meeting at the venue.

The requisite quorum being present, the Meeting was called to order.

4. WELCOME AND INTRODUCTION

The meeting commenced with a welcome address by Mr. Kiran Durugkar, Anchor for the AGM, who welcomed the Members, Directors, senior management, auditors and other distinguished guests present at the meeting.

The Anchor highlighted that the AGM was particularly significant as it was the first Annual General Meeting of the Company following the successful listing of its equity shares on the BSE SME Platform in May 2026.

The members of the Board and senior management present on the dais were introduced to the Members.

5. FORMAL OPENING OF THE MEETING

Thereafter, Ms. Ruchi Modi, Company Secretary & Compliance Officer, welcomed the Members and briefed them regarding the formal proceedings of the AGM.

The Members were informed that the Notice convening the 22nd AGM, together with the Annual Report for the financial year ended 31st March 2026, had been circulated to the Members in accordance with the applicable provisions of the Companies Act, 2013 and other applicable regulatory requirements.

The Company Secretary further informed the Members regarding the facility of remote e-voting provided by the Company. The Members were informed that the remote e-voting facility was made available from Tuesday, 25th August 2026 at 9:00 A.M. to Friday, 28th August 2026 at 5:00 P.M.

It was further informed that Members who had already exercised their voting rights through remote e-voting could attend the AGM but would not be entitled to vote again at the meeting. Members who had not exercised their votes through remote e-voting were provided an opportunity to cast their votes through ballot paper during the AGM.

The Company had appointed M/s. Avinash Gandhewar & Associates as Scrutinizer for scrutinizing the voting process and submitting the Scrutinizer's Report.

6. FINANCIAL PERFORMANCE FOR FY 2025-26:

Thereafter, Mr. Swapan Khandelwal, Whole-Time Director, addressed the Members and presented the financial performance and key financial highlights of the Company for the financial year 2025-26.

The Members were informed that the Company's Revenue from Operations and Other Income increased from ₹2,805.57 lakhs in FY 2024-25 to ₹3,119.88 lakhs in FY 2025-26.

The Profit Before Tax increased from ₹385.84 lakhs to ₹538.54 lakhs, while Profit After Tax increased from ₹283.43 lakhs to ₹411.71 lakhs. The Earnings Per Share also improved from ₹4.11 to ₹5.97.

The Whole-Time Director further apprised the Members about the Company's business model, operational focus and priorities for FY 2026-27, including expansion of the customer base, strengthening of market presence, improvement in operational capabilities, adoption of technology, process optimisation and pursuit of sustainable and profitable growth.

7. BUSINESS JOURNEY, MARKET INSIGHTS AND FUTURE OUTLOOK:

Thereafter, Mr. Prashant Karkare, Executive Director, addressed the Members and shared his perspective on the Company's journey from market insights to market leadership.

He apprised the Members about the competitive and evolving pharmaceutical market, the Company's focus on strengthening its product portfolio, improving engagement with the medical fraternity, expanding geographical presence and strengthening its sales and marketing capabilities.

He further stated that the Company would focus on developing meaningful and sustainable brands and exploring opportunities in specialty and super-specialty segments.

The Members were also informed that the successful listing of the Company on the BSE SME Platform marked the beginning of a new phase of growth and greater responsibility towards all stakeholders.

8. ADDRESS BY THE CHAIRMAN & MANAGING DIRECTOR

Thereafter, Mr. Amol Mujumdar, Chairman & Managing Director**,** addressed the Members.

The Chairman & Managing Director welcomed the Members and expressed his appreciation for their continued trust and confidence in the Company.

He highlighted the Company's journey, its foundation in pharmaceutical expertise, customer relationships, quality products and long-term growth, and acknowledged the contribution of employees, customers, business partners, advisors, associates and shareholders.

He further stated that the successful listing of the Company had strengthened its financial foundation and enhanced its visibility in the capital markets.

The Chairman & Managing Director reiterated the Company's commitment to transparency, corporate governance, regulatory compliance, responsible financial management and sustainable value creation.

He thereafter placed before the Members the agenda items forming part of the 22nd AGM.

9. BUSINESS ITEMS / AGENDA

The following items of business were placed before the Members for their consideration and approval:

ORDINARY BUSINESS

Item No. 1 – Adoption of Financial Statements

To receive, consider and adopt the Standalone Audited Balance Sheet as at 31st March 2026, the Statement of Profit and Loss for the financial year ended on that date, the Cash Flow Statement, together with the Auditors' Report and Directors' Report thereon.

Item No. 2 – Declaration of Dividend

To declare dividend of ₹12/- per preference share of face value of ₹100/- each for the financial year 2025-26.

Item No. 3 – Re-appointment of Director

To re-appoint Mr. Prashant Shrikrishna Karkare (DIN: 06572686) as Executive Director, who retires by rotation and, being eligible, offers himself for re-appointment.

SPECIAL BUSINESS

Item No. 4 – Material Related Party Transactions with Activista Healthcare Private Limited

To approve the existing as well as proposed new material related party transactions with Activista Healthcare Private Limited.

Item No. 5 – Material Related Party Transactions with Nucleage Pharma Solutions Private Limited

To approve the existing as well as proposed new material related party transactions with Nucleage Pharma Solutions Private Limited.

Item No. 6 – Material Related Party Transactions with Numerius Healthcare Private Limited

To approve the existing as well as proposed new material related party transactions with Numerius Healthcare Private Limited.

Item No. 7 – Borrowing of Unsecured Loans from Directors

To approve the borrowing of unsecured loans from Directors, with an option for conversion into equity shares.

Item No. 8 – Loans, Guarantees and Securities

To approve the proposal to advance any loan, including any loan represented by a book debt, or give any guarantee or provide any security in connection with any loan taken by any entity in which any Director is deemed to be interested, or to advance any loan to the Managing Director or Whole-Time Director of the Company.

10. ADDRESS BY THE NON-EXECUTIVE DIRECTOR

Thereafter, Dr. Prashant Rahate, Non-Executive Director, addressed the Members.

He spoke about the Company's long-standing presence in the pharmaceutical sector and emphasised the importance of quality, trust and commitment in the healthcare industry.

He further highlighted the increased responsibilities of the Company following its listing and reiterated the importance of strong corporate governance, transparency, regulatory compliance and disciplined execution.

He expressed confidence in the Company's ability to build upon its existing foundation and create sustainable long-term value for its shareholders and other stakeholders.

11. VOTING THROUGH BALLOT PAPER

Thereafter, Ms. Ruchi Modi, Company Secretary & Compliance Officer, explained the procedure for voting through ballot paper.

The Members who had already exercised their voting rights through remote e-voting were informed that their votes had already been recorded and that they were not required to vote again through ballot paper.

Members who had not exercised their voting rights through remote e-voting were requested to cast their votes through the ballot paper provided to them.

The Members were instructed to carefully read the resolutions and mark their choice appropriately against each resolution. They were further advised to avoid unnecessary markings or alterations and to deposit the duly completed ballot paper in the ballot box provided for the purpose.

It was informed that the votes cast through ballot paper, together with the votes received through remote e-voting, would be considered for determining the voting results of the resolutions placed before the Members.

The Scrutinizer would consolidate and scrutinize the votes and submit the Scrutinizer's Report to the Company. The voting results would be declared within 48 hours of the conclusion of the meeting and would be placed on the Company's website and communicated to the Stock Exchange in accordance with the applicable requirements.

12. VOTE OF THANKS AND CONCLUSION

Thereafter, the Anchor thanked the Members for their participation and continued confidence in the Company.

The Company expressed its appreciation to the Members, Directors, employees, customers, business partners, auditors, advisors and other stakeholders for their continued support and contribution to the Company's growth journey.

The Company also acknowledged the contribution of various distinguished individuals associated with the Company's journey and felicitated them with mementoes as a token of appreciation.

Thereafter, the Anchor thanked the members of the dais and all participants for their valuable presence and contribution to the AGM.

There being no other business to transact, the 22nd Annual General Meeting of Goldline Pharmaceutical Limited was concluded with a vote of thanks to the Chair.

The Members and guests were thereafter invited to join for refreshments and high tea.

For Goldline Pharmaceutical Limited

Ruchi Sanket Modi
Digitally signed by Ruchi Sanket Modi
Date: 2026.08.29 20:20:17 +05'30'

Ruchi Modi
Company Secretary & Compliance Officer

Date: 29th August, 2026
Place: Nagpur